TLRY Tilray

Tilray Brands Announces 420 Concert with Multi-Platinum Artist Don Toliver

Tilray Brands Announces 420 Concert with Multi-Platinum Artist Don Toliver

Celebrate 420 with Tilray’s Leading Cannabis Brands and Nationwide Activations Across Canada

TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- company (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, is set to elevate 420 celebrations across Canada with a series of dynamic consumer and industry events. This year's 420 festivities will spotlight Tilray's leading recreational cannabis brands—, , , and —through nationwide activations, pop-up events, and a marquee concert featuring multi-platinum artist on April 17, 2025, at , the iconic venue in Toronto, Ontario.

Set to be an unforgettable night, the Redecan 420 OG concert is designed to immerse attendees in a celebration of cannabis culture through music, interactive experiences, and exclusive perks. Don Toliver, renowned for his chart-topping tracks “No Idea,” “After Party,” “No Pole,” and “Bandit,” will headline the event, promising an electrifying performance that encapsulates the essence of 420. Celebrating alongside Redecan—a legacy Canadian cannabis brand that has grown from the ground up—420 OG emphasizes the community that has flourished over the years within cannabis culture, with a shared passion and deep-rooted respect for the plant.

420 OG Concert with Don Toliver Details:

  • When: Thursday, April 17th, 2025. Doors open at 8:00 PM
  • Where: Rebel, 11 Polson Street, Toronto, ON
  • Tickets:

In celebration of 420, the first 100 tickets will be available for just $42.00, starting March 3rd, 2025. These early access tickets can be purchased through Rebel and . The remaining tickets will be priced between $100 and $200.

Also at the concert, Redecan will introduce its unique and brand-new live resin product in its portfolio. The new LEGIT LIVE RESIN vapes are made from 100% fresh frozen flower, with no added terpenes. The vape comes in the brand’s most popular strains, Purple Churro and Animal Runtz, and comes in a 1.2g all-in-one format with a max THC of 1000mg.



Blair MacNeil, President of Tilray Canada, states, “We are thrilled to bring Canadians a 420 celebration like never before. Our concert with Don Toliver will be a monumental event, but the excitement doesn't stop there. Through our nationwide activations, we aim to create meaningful, educational, and immersive experiences for cannabis enthusiasts across the country. This is more than just a celebration—it's an opportunity to connect with our community, share our passion for cannabis, and showcase the innovation and quality of our brands."

Don’t miss out on the ultimate 420 celebration featuring Don Toliver. Get your  now! Follow @Tilray on all for updates on 420 activations.

About Tilray Brands 

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy, wellness and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on Tilray Brands, visit  and follow @Tilray.

Forward-Looking Statements  

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. 

For further information, please contact 

Media:  

Investors: 

Photos accompanying this announcement are available at:



EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tilray

 PRESS RELEASE

Tilray Brands and the Carlsberg Group Enter into an Exclusive Multi-Ye...

Tilray Brands and the Carlsberg Group Enter into an Exclusive Multi-Year U.S. Brewing and Commercial Partnership NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), a leading global consumer packaged goods company and the fourth-largest craft beer brewer in the United States, today announced that it has entered into an exclusive licensing agreement starting January 1, 2027 with the Carlsberg Group, one of the world’s premier brewing organizations and among the largest globally by revenue. Under the terms of the agreement, Tilray has been granted a m...

 PRESS RELEASE

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich...

Tilray erweitert den pharmazeutischen Zugang im Vereinigten Königreich durch eine strategische Vereinbarung mit Smartway Pharmaceuticals CC-Pharma-Vereinbarung fördert das Wachstum von Tilray im Vereinigten Königreich und stärkt den Vertrieb über Apotheken- und Krankenhauskanäle NEW YORK und LONDON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass ihr europäisches pharmazeutisches Vertriebsunternehmen CC Pharma eine strategische Vereinbarung mit , einem führenden pharmazeutischen Vertriebspartner...

 PRESS RELEASE

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni g...

Tilray élargit son accès aux produits pharmaceutiques au Royaume-Uni grâce à un accord stratégique avec Smartway Pharmaceuticals L’accord avec CC Pharma renforce la croissance de Tilray au Royaume-Uni, consolidant sa distribution auprès des pharmacies et des hôpitaux NEW YORK et LONDRES, 13 févr. 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, la division pharmaceutique de Tilray Brands, Inc. (Nasdaq : TLRY ; TSX : TLRY), a annoncé aujourd'hui que son activité de distribution pharmaceutique européenne, CC Pharma, a conclu un accord stratégique avec , un partenaire de distribution pharmaceutique...

 PRESS RELEASE

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement wi...

Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals CC Pharma Agreement Bolsters Tilray’s UK Growth, Strengthening Distribution to Pharmacy and Hospital Channels NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), today announced that its European pharmaceutical distribution business, CC Pharma, has entered into a strategic agreement with , a leading UK-based pharmaceutical distribution partner, to expand the availability of pharmaceutical products...

 PRESS RELEASE

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in De...

CC Pharma von Tilray als eines der 100 innovativsten Unternehmen in Deutschland ausgezeichnet Die Auszeichnung würdigt CC Pharma als innovativen Marktführer und vertrauenswürdigen Partner auf dem europäischen Pharmamarkt DENSBORN, Deutschland, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), gab heute bekannt, dass , ihr europäischer Pharmahändler, zu einem der ernannt wurde. Hierbei handelt es sich um eine der renommiertesten und unabhängigsten Auszeichnungen für Innovation bei kleinen und mittleren Unternehmen des La...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch